Additional risk minimisation measures in the EU - are they eligible for assessment?

Area of Science:

• Pharmacovigilance and Drug Safety
• Health Informatics
• Regulatory Science

Background:

• Additional risk minimization measures (aRMMs) are vital for optimizing drug benefit-risk balance.
• European Union (EU) pharmacovigilance legislation mandates the evaluation of aRMM effectiveness since July 2012.
• Assessing aRMM effectiveness is essential for ensuring drug safety and regulatory compliance.

Purpose of the Study:

• To classify aRMMs implemented in the EU.
• To identify the potential for analyzing aRMM effectiveness using existing electronic healthcare databases (EHDs).
• To understand the limitations of EHDs in evaluating drug safety measures.

Main Methods:

• Review of European Public Assessment Reports to identify key elements of aRMMs.
• Categorization of aRMM key elements based on objectives (knowledge vs. behavioral change).
• Assessment of the eligibility of aRMM key elements for analysis in existing EHDs.

Main Results:

• 801 key elements from 68 drugs with aRMMs were analyzed.
• 57% of aRMM key elements targeted behavioral changes.
• Only 22% of all key elements, primarily behavioral recommendations for healthcare professionals, were deemed eligible for EHD analysis.

Conclusions:

• A limited proportion of aRMM key elements are suitable for monitoring in existing EHDs due to data capture limitations.
• The heterogeneity of EHDs means not all are appropriate for evaluating every drug or aRMM.
• Standardized, well-defined aRMM key elements are needed for effective evaluation and timely adjustments by industry and regulators.